Stability Study in Pharma: ICH Q1A(R2) Complete Guide

In short: A stability study shows how the quality of a drug substance or drug product changes with time under the influence of temperature, humidity and light, and it supports the re-test period or shelf life and the storage label. This guide takes QC, QA and regulatory staff through ICH Q1A(R2): batches, storage conditions, testing frequency, significant change, stress and photostability testing, evaluation, climatic zones (India is a hot and humid market), ongoing stability and chamber control, with a fictional worked example and FAQs.

Why stability studies matter

Every batch of a medicine carries an expiry date and a storage statement. Both rest on stability data. The purpose of a stability study, in the words of ICH Q1A(R2), is to provide evidence on how quality varies over time under environmental factors such as temperature, humidity and light, and so to establish a re-test period for a drug substance or a shelf life for a drug product, together with recommended storage conditions.

Regulations point the same way. In the US, 21 CFR 211.166(a) requires a written stability testing program whose results are used to determine storage conditions and expiration dates, with statistically based sample size and test intervals, specific test methods, and testing in the marketed container-closure system. 21 CFR 211.137 links the label expiry date to that testing. The test methods must be stability-indicating, shown through forced degradation and validation.

For a shorter introduction with the zone table, see why stability testing matters. This guide is the full walk-through.

The ICH stability family

Q1A(R2) is the current Step 4 text of the parent guideline (6 February 2003). WHO Annex 10 explains that ICH withdrew Q1F, so conditions for zones III and IV now come from WHO.

Is there a new consolidated ICH Q1?

Yes, in draft. A consolidated revision of the Q1 guidelines reached Step 2 in April 2025 and is expected to reach Step 4 in late 2026; until then Q1A(R2) to Q1E apply. ICH is combining Q1A(R2), Q1B, Q1C, Q1D, Q1E and the biotech guideline Q5C into one text titled “Stability Testing of Drug Substances and Drug Products”. The Step 2 draft was released for public consultation, and the US FDA published it as a draft guidance in June 2025. No Step 4 text had been confirmed at the time of writing, so the separate Q1A(R2) to Q1E texts remain the ones to follow, and even after Step 4 a guideline applies in each region only once the regulator implements it.

Study design under Q1A(R2)

Batches

Q1A(R2) asks for data from at least three primary batches of the drug substance, made to at least pilot scale by the same synthetic route and a procedure that simulates the final process. For a drug product, data should come from at least three primary batches of the same formulation, packed in the container-closure system proposed for marketing. Two of the three batches should be at least pilot scale, the third may be smaller if representative of the critical manufacturing steps, and wherever possible different batches of drug substance should be used. Stability studies are done on each strength and container size unless bracketing or matrixing is applied.

Container-closure system and attributes

Test the product in the packaging proposed for marketing. Choose attributes that are susceptible to change and can affect quality, safety or efficacy: for a tablet typically appearance, assay, degradation products, dissolution, water content and microbial limits as appropriate. The methods must be stability-indicating and validated.

Storage conditions and minimum data at submission

For the general case, Q1A(R2) sets these conditions. The same table applies to drug substances and drug products.

Things to note:

• The applicant decides whether long-term studies are run at 25/60 or 30/65. If 30/65 is the long-term condition, there is no intermediate condition.
• If long-term is 25/60 and significant change occurs at any time during the 6 months at accelerated, intermediate testing is required, and the initial application should include at least 6 months of data from a 12-month study at intermediate.
• Other conditions apply to products stored in a refrigerator (long-term 5 °C ± 3 °C for 12 months, accelerated 25 °C / 60% RH for 6 months) and in a freezer (long-term −20 °C ± 5 °C with a 12-month minimum at submission, plus testing of a single batch at an elevated temperature, for example 5 °C ± 3 °C or 25 °C ± 2 °C, for an appropriate period), to semi-permeable containers (this applies to aqueous-based products; water loss is assessed, with long-term at 25 °C / 40% RH or 30 °C / 35% RH and accelerated at 40 °C ± 2 °C / not more than 25% RH) and to impermeable containers, where humidity is not a concern.
• Alternative conditions can be used if justified.

Testing frequency

For a product with a proposed shelf life of at least 12 months, Q1A(R2) says testing at the long-term condition should normally be every 3 months in the first year, every 6 months in the second year, and annually after that through the proposed shelf life. In practice that is 0, 3, 6, 9, 12, 18, 24 months and then 36 months and so on. At the accelerated condition the guideline recommends at least three time points including the first and last (for example 0, 3 and 6 months); if you expect results to approach significant change, add extra samples at the final time point or a fourth time point. For intermediate testing, a minimum of four time points including the first and last (for example 0, 6, 9 and 12 months) is recommended.

Significant change

For a drug substance, significant change is failure to meet its specification. For a drug product, Q1A(R2) generally defines it as:

1. A 5% change in assay from the initial value (or failure to meet potency criteria for biological procedures).
2. Any degradation product exceeding its acceptance criterion.
3. Failure to meet the acceptance criteria for appearance, physical attributes and functionality tests (colour, phase separation, hardness, dose delivery and so on), recognising that some physical changes, such as softening of suppositories, may be expected under accelerated conditions.
4. As appropriate for the dosage form, failure to meet the pH criterion.
5. As appropriate for the dosage form, failure to meet the dissolution criteria for 12 dosage units.

Significant change at accelerated storage is the trigger for intermediate testing when long-term is 25/60 and affects what shelf life you can claim.

Stress testing and photostability

Stress testing of the drug substance helps identify likely degradation products, establish degradation pathways and intrinsic stability, and show that the analytical methods are stability-indicating. Q1A(R2) says it is likely to be done on a single batch and should include the effect of temperature in 10 °C steps above the accelerated temperature (for example 50 °C, 60 °C), humidity (75% RH or more where appropriate), oxidation, photolysis and hydrolysis across a wide pH range for solutions or suspensions.

Photostability is an integral part of stress testing and is covered by ICH Q1B. For confirmatory studies the samples should be exposed to light giving an overall illumination of not less than 1.2 million lux hours and an integrated near-ultraviolet energy of not less than 200 watt hours per square metre, using either an actinometric system or calibrated radiometers and lux meters. For drug products, Q1A(R2) asks for photostability testing on at least one primary batch if appropriate.

Reduced designs: bracketing and matrixing

When there are many strengths, pack sizes and fills, testing every combination at every time point is expensive. ICH Q1D defines two reduced designs: bracketing, in which only samples at the extremes of certain design factors (for example strength or container size) are tested at all time points, and matrixing, in which a selected subset of samples for all factor combinations is tested at a given time point. Any reduced design must be able to predict the shelf life adequately and must be justified; Q1D notes that matrixing has limited use, and bracketing is generally not applicable, for drug substances. For the design rules, see bracketing and matrixing designs under ICH Q1D.

When the filing has data for less than the proposed shelf life, a commitment to continue the studies on production batches is normally made.

Evaluation and shelf life (ICH Q1E)

Q1E describes how to evaluate the data and set the shelf life:

• For an attribute that changes with time, statistical analysis of long-term data is useful. The usual approach is to find the earliest time at which the 95% confidence limit for the mean intersects the acceptance criterion: the lower one-sided limit for an attribute that decreases (such as assay), the upper one-sided limit for one that increases (such as a degradation product), and two-sided limits when the direction is unknown.
• Extrapolation beyond the period covered by real-time data may be proposed, but the proposed shelf life can be up to twice, and no more than 12 months beyond, the period covered by long-term data, supported by the analysis and by relevant supporting data (such as accelerated results and mass balance).
• Significant change at accelerated conditions limits what can be proposed and may require data from intermediate storage.

Climatic zones and where India fits

The storage conditions for stability studies depend on the climate where the product will be stored. WHO TRS 1010 Annex 10 (2018) gives the long-term conditions as below.

Annex 10 gives long-term conditions for these zones.

The long-term condition (25/60, 30/65 or 30/75) follows the climatic zone of the intended market; testing at a more severe condition is an acceptable alternative. For impermeable containers (for example glass ampoules) moisture is not a concern (WHO TRS 1010 Annex 10, 2018). Where 30/65 or 30/75 is the long-term condition, there is no intermediate condition.

India is a hot and humid country and is treated as a zone IV market. Many manufacturers plan Indian and other tropical-market products on zone IVb (30 °C / 75% RH), usually with 40 °C / 75% RH accelerated. WHO’s “Stability conditions for WHO Member States by Region” (March 2021) lists India at 30 °C / 70% RH (entry received through official channels). 30 °C / 75% RH is the more severe condition and covers it.

Ongoing stability programme (EU GMP Chapter 6)

After marketing, EU GMP Part I Chapter 6 (2014 revision) expects a continuous, written ongoing stability programme under the heading “On-going stability programme” (§6.26 to §6.36):

An out-of-specification or atypical trend result in the programme is handled like any other OOS: see the OOS investigation guide and the deviation management guide.

Stability chambers: qualification and excursions

• Qualification: after installation and operational checks, map temperature and humidity at many positions, empty and loaded, and demonstrate recovery after a door opening and a power failure. EU GMP Chapter 6 §6.29 says chambers should be qualified and maintained.
• Monitoring: continuous recording with alarms, calibrated probes and periodic data review. See the example SOPs on recording temperature and humidity of a stability chamber and temperature and relative humidity monitoring.
• Tolerances: Q1A(R2) sets conditions with tolerances such as ± 2 °C and ± 5% RH. The glossary accepts short spikes from door opening as unavoidable, but says the effect of excursions from equipment failure should be addressed and reported if they affect results, and that excursions exceeding the tolerances for more than 24 hours should be described in the study report and their effect assessed.

Example in-house criterion for a chamber programme, to be adapted by each site:

If an excursion occurs, record its start, end, size and the samples affected; compare it with the tolerance and the 24-hour point in Q1A(R2); assess the likely effect given the product’s sensitivity and trend data; and document the decision.

Worked example (fictional)

A fictional company, Greenfield Labs, wants to register “Examplamol 500 mg tablets” for India and other tropical markets.

1. Design. Three primary batches (two pilot scale, one smaller and representative) are packed in Alu-Alu blisters and in HDPE bottles. Long-term is 30 °C / 75% RH (zone IVb), accelerated 40 °C / 75% RH for 6 months, with no intermediate condition because long-term is 30/75. Photostability is run on one batch under Q1B. Long-term pulls are at 0, 3, 6, 9, 12, 18 and 24 months, then yearly; accelerated pulls at 0, 3 and 6 months.
2. Six-month accelerated result. The blisters show no significant change. In the bottles, Impurity A rises above its limit, which is significant change under Q1A(R2). The team drops the bottle for this filing and keeps the bottle result as supporting information on moisture sensitivity.
3. 18-month evaluation. Assay of the blister batches trends from 100.4% to 98.9%, the batches pass the poolability test, and the lower one-sided 95% confidence limit of the pooled regression reaches the 95.0% limit at about 31 months. Impurity A rises slowly and stays within its limit.
4. Proposal. With 18 months of real-time data, Q1E would allow up to twice that period but not more than 12 months beyond it, that is 30 months. The company proposes a conservative 24 months with the statement “Store below 30 °C. Protect from moisture”, and commits to continue the studies on production batches.
5. After launch. One batch per year enters the ongoing programme (EU GMP Chapter 6 §6.32). In year two, a chamber alarm records a 3 hour excursion to 33 °C; the assessment finds no trend change in the affected samples and the decision is recorded.

This example is fictional and uses no real data.

Common mistakes

• Testing in a pack that differs from the marketed pack.
• Loose pull dates: set an example in-house criterion for the allowed window and document any use.
• Extrapolating further than Q1E allows.
• Ignoring significant change at accelerated conditions, or having no chamber backup.

Record retention

Stability protocols, raw data, chamber records and reports are GMP records. Records specifically associated with a batch must be kept at least 1 year after the expiry date of the respective product batch (EU GMP Part I Chapter 4 §4.11, or 5 years after QP certification if that is longer; 21 CFR 211.180(a)), and longer if local law or the marketing authorisation requires.

Frequently asked questions

What is the difference between a stability study and ongoing stability?

A formal study supports the first shelf life using primary batches. The ongoing programme monitors marketed batches to confirm that the shelf life stays valid.

Which long-term condition should an Indian manufacturer choose?

For products meant for hot and humid markets, many use 30 °C / 75% RH. WHO’s “Stability conditions for WHO Member States by Region” (March 2021) lists India at 30 °C / 70% RH (entry received through official channels); 30 °C / 75% RH is the more severe condition and covers it.

When is intermediate testing needed?

When long-term is 25 °C / 60% RH and significant change occurs during the 6 months at accelerated conditions. If long-term is 30/65 or 30/75 there is no intermediate condition.

How long can the shelf life be extrapolated?

Under Q1E, up to twice the period covered by long-term data and no more than 12 months beyond it, when supported by statistical analysis and supporting data. Without such support, the extent is more limited.

Is photostability testing always required?

Q1A(R2) asks for photostability testing on at least one primary batch of the drug product “if appropriate”, using Q1B conditions. Justify any omission.

Does ICH Q1 replace Q1A(R2)?

A consolidated Q1 is in draft. Until it is adopted and implemented by your regulator, follow the existing guidelines.

References

1. ICH Q1A(R2), Stability Testing of New Drug Substances and Products, Step 4 (6 February 2003), sections 2.1.2, 2.1.3, 2.1.6, 2.1.7, 2.2.2, 2.2.3, 2.2.6, 2.2.7, 2.2.9 and Glossary. ich.org.
2. ICH Q1B, Photostability Testing of New Drug Substances and Products, section C (Procedure). ich.org.
3. ICH Q1D, Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products, section 2. ich.org.
4. ICH Q1E, Evaluation of Stability Data, sections 2.4 onward. ich.org.
5. ICH Q1, Stability Testing of Drug Substances and Drug Products, draft guideline at Step 2 (April 2025). ich.org; US FDA draft guidance (June 2025). fda.gov.
6. WHO Technical Report Series No. 1010 (2018), Annex 10: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. who.int.
7. European Commission, EudraLex Volume 4, EU GMP Part I Chapter 6: Quality Control (2014 revision), On-going stability programme, §6.26 to §6.36. health.ec.europa.eu.
8. European Commission, EudraLex Volume 4, EU GMP Part I Chapter 4: Documentation, §4.11. health.ec.europa.eu.
9. US FDA, 21 CFR 211.166, Stability testing; 21 CFR 211.137, Expiration dating; 21 CFR 211.180(a), General requirements for records. ecfr.gov.
10. WHO, Stability conditions for WHO Member States by Region (March 2021). cdn.who.int.